How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

987 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis Full Text available with Trip Pro

Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis House dust mite (HDM) allergy is a predominant cause for perennial allergic rhinitis (AR) in Europe. We recently reported that circulating erythrocyte numbers decrease after airway allergen challenge in a murine asthma model and in grass-pollen sensitized AR subjects. Consequently, we aimed to evaluate these findings in HDM sensitized AR subjects (...) and the influence of preceding allergen immunotherapy. Seventy-seven (age 26.8 ± 7.3 years; 54.5% female) HDM-allergic rhinitis subjects previously enrolled in a randomized, monocentric sublingual immunotherapy (SLIT) trial at the Vienna Challenge Chamber (VCC) were included. Subjects had either received placebo (n = 22), low-dose HDM (n = 29) or high-dose HDM specific sublingual immunotherapy (n = 26) daily for 24 weeks. Blood sampling was performed before and after 6 hours of HDM allergen exposure. Overall

2017 Scientific reports Controlled trial quality: uncertain

82. Tinnitus after administration of sublingual immunotherapy Full Text available with Trip Pro

Tinnitus after administration of sublingual immunotherapy Sublingual immunotherapy was first described in 1986. Since then, its use has been increased as an alternative to subcutaneously administered immunotherapy in the treatment of allergic rhinitis. The most common side effects are of oropharyngeal and gastrointestinal in nature, for example, itching, swelling, irritation, ulceration of the oropharynx and nausea, abdominal pain, diarrhoea, and vomiting. More severe side effects are dominated (...) by systemic and respiratory tract manifestations.In this clinical case, the author reports a right-sided transient tinnitus lasting for 48 h after administration of sublingual immunotherapy for house dust mite in allergic rhinitis.This case provide important insights for clinical practice, as tinnitus has not been previously reported as a side effect of sublingual immunotherapy with house dust mite allergens.

2017 SAGE Open Medical Case Reports

83. Erratum: In Vitro Evaluation of Allergen Potencies of Commercial House Dust Mite Sublingual Immunotherapy Reagents Full Text available with Trip Pro

Erratum: In Vitro Evaluation of Allergen Potencies of Commercial House Dust Mite Sublingual Immunotherapy Reagents This corrects the article on p. 124 in vol. 7, PMID: 25729619.

2017 Allergy, asthma & immunology research

84. Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center Full Text available with Trip Pro

Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center Many placebo-controlled studies have demonstrated that allergen immunotherapy (AIT) is an effective therapy for treating allergies. Both commonly used routes, subcutaneous (SCIT) and sublingual immunotherapy (SLIT), require high patient adherence to be successful. In the literature, numbers describing adherence vary widely; this investigation compares these two routes of therapy directly.All data

2017 Patient preference and adherence

85. Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children Full Text available with Trip Pro

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children This review presents up-to-date understanding of immunotherapy in the treatment of children with allergic asthma. The principal types of allergen immunotherapy (AIT) are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both of them are indicated for patients with allergic rhinitis and/or asthma, who have evidence of clinically relevant allergen-specific IgE, and significant symptoms despite reasonable

2017 Frontiers in pediatrics

86. Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen Full Text available with Trip Pro

Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen Immunotherapy by sublingual administration of allergens provides high patient compliance and has emerged as an alternative to subcutaneous immunotherapy for the treatment of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause adverse events. Development of allergen delivery systems enabling more efficient delivery and hence lower allergen load might reduce the adverse events (...) . In the present study, we have investigated neutral and cationic liposomes as delivery systems of ovalbumin (OVA), as a model allergen, in an OVA-induced allergic airway inflammation model. We investigated the liposome carriers' ability to improve tolerance induction of antigens compared to the corresponding dose of free OVA. Mice were treated sublingually over 2 weeks with free or liposome encapsulated OVA followed by intraperitoneal injections and intranasal challenge. Mice sublingually treated with OVA

2017 International journal of nanomedicine

87. Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. (Abstract)

Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. Sublingual allergen immunotherapy (SLIT) is considered to be safer and more convenient than subcutaneus immunotherapy. SLIT trials with house dust mites involving patients with allergic rhinitis (AR) and asthma reported discordant results. The aim of the study was to investigate the clinical efficacy and safety of SLIT with Dermatophagoides pteronyssinus (D.pt) extract produced in Serbia and patient's

2017 Iranian journal of allergy, asthma, and immunology Controlled trial quality: uncertain

88. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. (Abstract)

A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Treatment with allergy immunotherapy improves allergic rhinoconjunctivitis, but can also improve comorbidities associated with allergic rhinitis such as asthma. Sublingual immunotherapy (SLIT)-tablets are a convenient and efficacious method of allergy immunotherapy. They are self-administered after the first tablet has been provided under medical supervision. Therapy may elicit

2017 Postgraduate medicine Controlled trial quality: uncertain

89. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. (Abstract)

Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. Allergy immunotherapy can result in systemic allergic reactions and even life-threatening anaphylaxis requiring epinephrine administration.The objective of this study was to describe epinephrine use in the clinical trial development programs of 3 rapidly dissolving sublingual immunotherapy tablets (SLIT-tablets; Merck & Co., Inc., Kenilworth, NJ/ALK, Hørsholm, Denmark/Torii Pharmaceutical Co., Ltd., Tokyo, Japan).Data

2017 The journal of allergy and clinical immunology. In practice Controlled trial quality: uncertain

90. Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment

Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S

2017 Clinical Trials

91. Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. (Abstract)

Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. To sustain the long-lasting beneficial effects of allergen-specific sublingual immunotherapy (SLIT), an adequate duration of treatment is required. Nevertheless, many patients discontinue prematurely and therefore fail to obtain satisfactory therapeutic effect in clinical practice. The aim of this study was to analyze the causes leading to premature discontinuation of SLIT in allergic rhinitis (AR (...) ), and to provide the corresponding countermeasures for the following SLIT course.We performed a retrospective analysis of data from 142 patients with AR who started SLIT during the period from December 2009 to February 2015. Patients were contacted at 1, 3, 6, and 12 months into SLIT as part of our standard of care. The patients who claimed to have stopped treatment were asked to provide a reason during one of the phone calls.Overall, 76 (54%) patients with AR terminated immunotherapy during the first year

2017 International forum of allergy & rhinology

92. Perceived compliance and barriers to care in sublingual immunotherapy. (Abstract)

Perceived compliance and barriers to care in sublingual immunotherapy. For allergy immunotherapy to be effective, patient compliance is critical. However, aqueous sublingual immunotherapy (SLIT) may be considered demanding for patients, requiring strict daily dosing and refilling of medication at regular intervals. In this study we sought to determine how patients perceive their own compliance with SLIT and identify barriers that may hinder compliance.Using a retrospective review, 46 patients

2017 International forum of allergy & rhinology

93. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients. (Abstract)

Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients. The prolonged effect of allergen immunotherapy is unknown, especially in older patients.To analyze the 3-year effect of sublingual allergen-specific immunotherapy (SLIT) to house dust mites in elderly patients with allergic rhinitis.Forty-seven elderly patients (65.78 ± 4.89 years old) underwent SLIT to house dust mites and were monitored for 3 years and compared with a placebo group. SLIT

2017 Asthma & Immunology

94. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. Full Text available with Trip Pro

Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents. House dust mite (HDM) respiratory allergy is a common and burdensome disease in children and adolescents. There are few HDM allergy immunotherapy trials in children with perennial allergic rhinitis. This post hoc analysis used pooled data to evaluate efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in adolescents (12-17 years).In two double-blind, placebo-controlled

2017 Pediatric Allergy and Immunology Controlled trial quality: predicted high

95. Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study. Full Text available with Trip Pro

Food-specific sublingual immunotherapy is well tolerated and safe in healthy dogs: a blind, randomized, placebo-controlled study. Food allergies are increasing in prevalence but no treatment strategies are currently available to cure dogs with food allergy. Over the past decade, experimental food allergen-specific sublingual immunotherapy (FA-SLIT) has emerged as a potential treatment for food allergies in human medicine. However, FA-SLIT has not been investigated in dogs. Therefore

2017 BMC veterinary research Controlled trial quality: uncertain

96. Hot Topics in Primary Care: Sublingual Immunotherapy: A Guide for Primary Care. (Abstract)

Hot Topics in Primary Care: Sublingual Immunotherapy: A Guide for Primary Care. Allergen immunotherapy (AIT), the only potential disease-modifying treatment for allergic disease, has been used for more than a century. Hankin et al showed significant reduction in pharmacy, outpatient, and inpatient resources in the 6 months following vs the 6 months preceding AIT in Medicaid-enrolled children with allergic rhinitis (AR). A 2013 analysis showed sustained cost reduction over 18 months in patients

2017 Journal of Family Practice

97. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Full Text available with Trip Pro

Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy immunotherapy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with long-term efficacy. However, there are few real-life data on the progression of AR and/or AA in patients receiving AIT.To assess the real-world, long-term efficacy of grass pollen sublingual immunotherapy (SLIT) tablets in AR

2017 Allergy

98. [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma]

[Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] S Shin, HJ Song, SY Park, YJ Jung, JY Park, J Ahn, YM Yea Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation S Shin, HJ Song, SY Park, YJ Jung, JY Park, J Ahn, YM Yea. [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-11-006. 2011 Authors' conclusions Disease burdens of allergic rhinitis and asthma have recently been

2011 Health Technology Assessment (HTA) Database.

99. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is a potential novel treatment option for HDM allergy-related asthma.To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period.Double-blind, randomized, placebo-controlled trial conducted

2016 JAMA Controlled trial quality: predicted high

100. Sublingual Immunotherapy

Sublingual Immunotherapy Sublingual Immunotherapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sublingual Immunotherapy Sublingual (...) Immunotherapy Aka: Sublingual Immunotherapy , Grastek , Oralair , Ragwitek From Related Chapters II. Indications Allergy For allergic symptoms refractory to standard allergy medications III. Precautions Not to be used without formal ing first Observe in office for first sublingual dose All patients should receive auto-injector in case of reaction IV. Preparations Grass allergies Grastek Oralair Ragweed allergy Ragwitek V. Dosing: Protocol Start medication 3-4 months prior to allergy season and continue

2018 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>